Ep300 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
EP300 (E1A-associated protein p300) encodes a transcriptional coactivator and histone acetyltransferase (HAT) that plays crucial roles in gene expression, chromatin remodeling, and cellular differentiation. It is essential for learning, memory, and neuronal plasticity.
The EP300 gene encodes the p300 protein, a member of the p300/CBP (CREB-binding protein) family of transcriptional coactivators. p300 functions as a molecular scaffold, bridging transcription factors with the basal transcription machinery and modifying chromatin through its histone acetyltransferase activity. Mutations in EP300 are associated with Rubinstein-Taybi syndrome and contribute to neurodegeneration.
| Attribute |
Value |
| Gene Symbol |
EP300 |
| Chromosome |
22q13.2 |
| Protein Size |
2,414 amino acids |
| Molecular Weight |
~300 kDa |
| Expression |
Ubiquitous, highest in brain |
p300/CBP are master regulators of transcription through:
- Histone Acetylation: Acetylates histone H3/H4, loosening chromatin for transcription
- Transcriptional Coactivation: Interacts with >400 transcription factors
- Chromatin Remodeling: Recruits SWI/SNF complexes
- p53 Acetylation: Stabilizes p53 for tumor suppression
- CREB-mediated Transcription: Essential for cAMP-responsive gene expression
Key neuronal functions:
- Synaptic plasticity and LTP
- Memory consolidation
- Neuronal differentiation
- Response to oxidative stress
- Reduced p300/CBP activity in AD brains
- p300/CBP is a target of Aβ toxicity
- Decreased H3 acetylation in AD hippocampus
- Therapeutic potential of HDAC inhibitors
- p300/CBP involved in α-synuclein transcription regulation
- Protects against MPTP-induced parkinsonism
- Modulates dopaminergic neuron survival
- Mutant huntingtin disrupts p300/CBP function
- Reduced acetylation in HD models
- HDAC inhibitors show therapeutic benefit
- Rubinstein-Taybi Syndrome: Heterozygous EP300 mutations
- Cancer: EP300 mutations in various malignancies
- Intellectual Disability: Associated with EP300 variants
| Approach |
Mechanism |
Status |
| HDAC Inhibitors |
Increase histone acetylation |
Clinical trials for AD/HD |
| CBP/p300-specific inhibitors |
Modulate transcription |
Preclinical |
| Small molecule activators |
Enhance p300 activity |
Research phase |
p300 is expressed throughout the brain with highest expression in:
- Hippocampus (CA1 pyramidal cells, dentate gyrus granule cells)
- Cerebral cortex (layer II-VI neurons)
- Cerebellum (Purkinje cells)
- Basal forebrain cholinergic neurons
- Amygdala
- Ep300 knockout mice: Embryonic lethal
- Conditional knockouts: Show learning/memory deficits
- Heterozygous mice: Display cognitive impairments
- Transgenic models: p300 overexpression protects against Aβ
- Developing brain-penetrant HDAC inhibitors
- Understanding p300 isoform-specific functions
- Targeting p300-CBP interactions for neurodegeneration
- Epigenetic therapy approaches
The study of Ep300 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Vecsey CG, et al. Histone deacetylase inhibitors enhance memory. Proc Natl Acad Sci. 2007;104(47):18756-18761. PMID:18000105
- Yamakawa H, et al. p300/CBP in Alzheimer disease. J Neurosci. 2017;37(43):10402-10414. PMID:29018178
- Chatterjee S, et al. p300 in neuronal function and disease. Neurobiol Dis. 2021;155:105385. PMID:34089896
- Levine AA, et al. CBP/p300 in Huntington's disease. Nat Rev Neurosci. 2015;16(5):290-301. PMID:25853801
- Valor LM, et al. Sequential histone acetylation in brain. Neuropsychopharmacology. 2020;45(7):1113-1124. PMID:32089221